Chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene were found in approximately one in 20 patients with non-small cell lung carcinoma (NSCLC). Since these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib, they have considerable implications for treatment. However, current diagnostic tests have limitations. Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC. ...Tuesday, 18 December 2012
Patients Most Likely to Benefit from ALK Inhibition Therapy: Novel Test
Chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene were found in approximately one in 20 patients with non-small cell lung carcinoma (NSCLC). Since these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib, they have considerable implications for treatment. However, current diagnostic tests have limitations. Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC. ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment